Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

Share Price is delayed by 15 minutes
Get Live Data
8.85    0.45 (5.36%)
Bid:
8.70
Ask:
9.00
Spread: 0.30 (3.448%)
Market Cap: £60.92m
HVO Live PriceLast checked at - London Stock Exchange

Intraday hVIVO Share Chart

Form 8.5 (EPT/RI) - hVIVO plc

16 Dec 2019 10:00

RNS Number : 9734W
Numis Securities Limited
16 December 2019
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Numis Securities Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

hVIVO plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Nominated Adviser to hVIVO plc

(d) Date dealing undertaken:

13/12/2019

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

None

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary 5p

Purchase

87,000

11.5000 GBX

11.5000 GBX

Ordinary 5p

Sale

14,000

12.3200 GBX

12.3200 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

16/12/2019

Contact name:

Naomi Brennan

Telephone number:

0207 260 1330

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEREANAKFSPNFEF
Date   Source Headline
1st Jun 202612:00 pmRNS-RConsultancy contract with Decoy Therapeutics
29th May 20267:00 amRNSGrant of awards under Long Term Incentive Plan
20th May 20267:00 amRNSCapital Markets Day
13th May 20261:40 pmRNSResult of AGM
12th May 20269:45 amRNSHolding(s) in Company
7th May 20267:00 amRNS£6m Influenza HCT contract signed
24th Apr 20266:14 pmRNSDirector/PDMR Shareholding
22nd Apr 20267:00 amRNSHCT contract signed with ILiAD Biotechnologies
17th Apr 20267:00 amRNSAnnual Report & Notice of AGM
15th Apr 20267:00 amRNSFinal Results 2025
14th Apr 20267:01 amRNS-RhVIVO launches unified brand identity
14th Apr 20267:00 amRNSInfluenza HCT contract signed with Traws Pharma
7th Apr 20267:00 amRNSNotice of Results
26th Mar 20265:19 pmRNSHolding(s) in Company
27th Feb 20263:31 pmRNSHolding(s) in Company
23rd Feb 20267:00 amRNSIssue of Equity and Total Voting Rights
16th Feb 20263:05 pmRNSHolding(s) in Company
11th Feb 20263:11 pmRNSHolding(s) in Company
29th Jan 20267:00 amRNSTrading Update
27th Jan 20267:00 amRNSNotice of Trading Update
18th Dec 20257:00 amRNSAppointment of Non-Executive Director
15th Dec 20252:47 pmRNSCEO & CFO Share Purchase
27th Nov 20257:00 amRNS-RMSD to acquire Cidara
20th Nov 20257:00 amRNS>£5 million CRS contracts signed
11th Nov 20257:00 amRNS-RPositive data from novel human challenge models
6th Nov 20255:05 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNS-RPresentation at Jefferies Healthcare Conference
27th Oct 20253:01 pmRNSHolding(s) in Company
23rd Sep 20257:00 amRNSInterim results
4th Sep 20257:00 amRNSNotice of Results
1st Sep 20257:00 amRNSAppointment of Non-Executive Chair
29th Jul 20257:00 amRNSProposed appointment of Chair
22nd Jul 20257:00 amRNSH1 Trading update
18th Jul 20257:00 amRNSDirectorate Change
9th Jul 20257:00 amRNSNotice of Trading Update
1st Jul 20254:04 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNS-RPositive results from client Phase 2b field study
5th Jun 20251:00 pmRNSResult of AGM
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSTrading update
29th May 20257:00 amRNSAppointment of Independent Non-Executive Director
12th May 20257:00 amRNSAnnual Report, Notice of AGM & Directorate Change
10th Apr 20257:05 amRNSExercise of Options
10th Apr 20257:00 amRNSFinal results
26th Mar 20251:51 pmRNSAIM Rule 17 and Schedule 2(g) Update
21st Mar 20257:00 amRNSNotice of Results
7th Mar 20257:00 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAcquisition of Cryostore for up to £3.2m
17th Feb 20257:00 amRNS£2m hMPV characterisation study contract
5th Feb 20257:00 amRNS-RShionogi reports positive RSV trial results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.